These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G. Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339 [Abstract] [Full Text] [Related]
7. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC. Vaccine; 2006 Mar 10; 24(11):1928-40. PubMed ID: 16310897 [Abstract] [Full Text] [Related]
10. Canine Leishmania vaccines: still a long way to go. Gradoni L. Vet Parasitol; 2015 Feb 28; 208(1-2):94-100. PubMed ID: 25620293 [Abstract] [Full Text] [Related]
11. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune. Araújo MS, de Andrade RA, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Vianna LR, Mayrink W, Reis AB, Malaquias LC, Mello MN, Martins-Filho OA. Vaccine; 2009 Feb 11; 27(7):1008-17. PubMed ID: 19110023 [Abstract] [Full Text] [Related]
16. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, Soares IS, Batista LM, Palatnik-de-Sousa CB. Vaccine; 2008 Sep 15; 26(39):4991-7. PubMed ID: 18675868 [Abstract] [Full Text] [Related]
17. IL-6 and TNF-alpha production during active canine visceral leishmaniasis. de Lima VM, Peiro JR, de Oliveira Vasconcelos R. Vet Immunol Immunopathol; 2007 Jan 15; 115(1-2):189-93. PubMed ID: 17097150 [Abstract] [Full Text] [Related]
18. Humoral immunological profile and parasitological statuses of Leishmune vaccinated and visceral leishmaniasis infected dogs from an endemic area. de Amorim IF, Freitas E, Alves CF, Tafuri WL, Melo MN, Michalick MS, da Costa-Val AP. Vet Parasitol; 2010 Oct 11; 173(1-2):55-63. PubMed ID: 20638182 [Abstract] [Full Text] [Related]
19. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V. Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705 [Abstract] [Full Text] [Related]
20. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs. de Andrade RA, Reis AB, Gontijo CM, Braga LB, Rocha RD, Araújo MS, Vianna LR, Martins-Filho OA. Vet Immunol Immunopathol; 2007 Mar 15; 116(1-2):85-97. PubMed ID: 17287029 [Abstract] [Full Text] [Related] Page: [Next] [New Search]